Pharmaceutical

CHMP backs MSD’s KEYTRUDA approval for urothelial carcinoma

The EMA CHMP has recommended approving MSD’s KEYTRUDA regimen as a first-line treatment for urothelial carcinoma.

Jul 30, 2024 - 04:00
CHMP backs MSD’s KEYTRUDA approval for urothelial carcinoma
The EMA CHMP has recommended approving MSD’s KEYTRUDA regimen as a first-line treatment for urothelial carcinoma.
Read the original article

Tags:

Previous Article

Bristol Myers Squibb reports dip in net income for Q2 2024

Next Article

New AI model boosts early osteoporosis diagnosis for ageing populations

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Novo Nordisk pauses ads for weight loss drug Wegovy as it struggles to meet demand

STAT+: Novo Nordisk pauses ads for weight loss drug Weg...

May 19, 2023

STAT+: A Harvard-affiliated hospital is testing magic mushrooms on dying patients

STAT+: A Harvard-affiliated hospital is testing magic m...

Nov 11, 2023

Generate:Biomedicines and Novartis link on protein therapeutics development

Generate:Biomedicines and Novartis link on protein ther...

Sep 26, 2024